EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer (ESP2011-002)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Esperance Pharmaceuticals Inc
ClinicalTrials.gov Identifier:
NCT01485848
First received: December 2, 2011
Last updated: December 20, 2013
Last verified: December 2013

December 2, 2011
December 20, 2013
February 2012
May 2014   (final data collection date for primary outcome measure)
  • Number of patients with dose limiting toxicities (DLTs) at different doses [ Time Frame: Up to 30 weeks ] [ Designated as safety issue: Yes ]
  • Overall Response Rate (ORR) [ Time Frame: Up to 30 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01485848 on ClinicalTrials.gov Archive Site
  • Time to Progression (TTP) - Time [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
  • Progression-free Survival - Time [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
  • Overall Survival (OS) - Time [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
  • Duration of Response - Time [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
  • Number of Participants with Adverse Events [ Time Frame: Up to 18 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial

Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any significant changes in the safety profile of weekly paclitaxel alone compared to the doublet combination of paclitaxel with EP-100. o Determine an initial benefit/risk profile for this new drug combination.

Total duration of the study for each participant is 9 to 10 months, consisting of a 1 month screening period, a 6 to 7 months treatment period, and a 30 day follow-up. All patients with stable disease or who have achieved partial or complete response and for whom dosing has been safe and reasonably well-tolerated may continue additional treatment cycles on the same regimen. Any patient whose imaging assessment shows disease progression after receiving at least two cycles of single agent weekly paclitaxel on ARM 1 may then be offered treatment with the combination of EP-100 plus paclitaxel in the same dose regimen as ARM 2.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Ovarian Cancer Recurrent
  • Drug: EP-100
    Pharmaceutical form:Solution Route of administration: Intravenous
  • Drug: Paclitaxel
    Pharmaceutical form:Solution Route of administration: Intravenous
  • Active Comparator: Paclitaxel
    A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)
    Intervention: Drug: EP-100
  • Experimental: Paclitaxel + EP-100
    Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)
    Intervention: Drug: Paclitaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
48
May 2014
May 2014   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Adult patients with histologically confirmed epithelial ovarian carcinomas; these will include primary peritoneal and fallopian tube carcinomas. Patient's tumor shown to be positive for the LHRH-receptors by standardized immunocytochemistry performed at the study's central laboratory.
  • Reliable cancer treatment history documenting advanced disease in patients who have progressed during or recurred after treatment with a paclitaxel and/or platinum regimen for advanced disease.
  • Evaluable disease based on criteria of the Gynecologic Intergroup Response Evaluation Criteria in in Solid Tumors.
  • Karnofsky performance status >/= 70%.

Exclusion criteria:

  • Significant cardiac disease.
  • Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
  • Pregnant or nursing women.
  • Treatment with radiation therapy or investigational therapy within 4 weeks prior to Day 1. Had received chemotherapy prior to study entry equivalent to 3 to 5 half-lives of that chemotherapy agent or 4 weeks prior to study entry (whichever is shorter) with resolution of any side effects from that previous therapy (6 weeks for nitrosoureas or Mitomycin C.)
  • Subjects with known central nervous system (CNS) metastases, either previously treated or current.
  • Disease-free and off therapy for any other cancer within 5 years, except for adequately treated basal cell or squamous cell skin cancer or cervical intraepithelial neoplasia (CIN).
  • Had major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1. o Had minor surgery (superficial incisions unlikely to obscure bleeding or infections) within 2 weeks prior to Day 1.
  • Potentially life-threatening disease (hypercalcemia, spinal cord compression) whose disease may progress acutely during therapy.
  • Unwilling or unable to comply with procedures required in this protocol.
  • Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • Susceptibility to histamine release.
  • Chronic treatment with corticosteroids.
  • Baseline QTc exceeding 450 msec (by Bazett's formula) and/or patients receiving class 1A or class III antiarrythmic agents.
  • Serious nonmalignant disease.
  • Subjects who are currently receiving any other investigational agent.
  • Inadequate renal and liver functions and bone marrow reserve.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01485848
ACT12601, U1111-1124-2062
No
Esperance Pharmaceuticals Inc
Esperance Pharmaceuticals Inc
Not Provided
Not Provided
Esperance Pharmaceuticals Inc
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP